This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...
Major Depressive Disorder (MDD) is one of the leading causes of disability worldwide, significantly impacting the working population by reducing productivity, increasing absenteeism, and impairing overall quality of life. Conventional treatments such as pharmacotherapy and psychotherapy, though effective, often face challenges including high dropout rates, limited remission, and adverse side...
BACKGROUND: Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy. About onethird of patients suffer from treatment-resistant depression (TRD), which emphasizes the urgent need for alternative therapies. This review aims to systematically evaluate the available data about...
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms. She experienced a relapse after a reduction in her maintenance treatment in conjunction with psychosocial stressors, but improved once again after returning to her induction regimen. She tolerated the...
Background Depression remains a leading cause of disability and suicide worldwide, with treatment-resistant depression (TRD) affecting nearly 30% of individuals diagnosed with major depressive disorder. Esketamine nasal spray (NS) and quetiapine extended-release (XR) are both approved as adjunctive therapies for TRD; however, direct head-to-head comparisons are limited. Method A systematic...
Treatment-resistant depression (TRD) is a heterogeneous condition in which symptoms such as anhedonia, rumination, and anxiety contribute to persistent disability. Esketamine nasal spray (ESK-NS), accelerated repetitive transcranial magnetic stimulation (arTMS), and adjunctive brexpiprazole represent novel therapeutic options with distinct mechanisms, though their domain-specific effects in...
Background: Major depressive disorder (MDD) affects over 280 million people globally and remains a leading cause of disability. Psilocybin has emerged as a promising treatment, with evidence suggesting modulation of neural oscillatory activity relevant to mood regulation. Electroencephalography (EEG) and magnetoencephalography (MEG) offer non-invasive methods for evaluating these...
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with...
Background: Pharmacologic treatment options for borderline personality disorder (BPD) remain limited, and no medication has received regulatory approval for its treatment. Given the high rates of comorbid depression and suicidal ideation in BPD, there is growing interest in novel therapeutic approaches. Ketamine has been approved for treatment-resistant depression and acute suicidality, raising...
Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use. Here, we found that increasing extracellular signal-regulated kinase (ERK) activity by pharmacologically...
Cell ReportsJuly 24, 2026Viktor J Oláh, Isabelle F Witteveen, Tue G Banke et al.
GABAergic inhibitory interneurons balance brain activity by suppressing excessive excitatory signaling and shaping network oscillations. Despite this critical function, our understanding of how neural circuits regulate GABAergic systems remains limited. Although N-methyl-D-aspartate receptor (NMDAR) functionality is defined by the GluN2A-D subunits, the interneuron NMDAR subunit composition...
Rapid clinical and EEG microstate changes 24 h after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.
MindfulnessJuly 22, 2026Kate Gliske, Gretchen Buchanan, Delaina Carlson et al.
Maternal mental health during pregnancy and the postpartum period is critical for offspring’s well-being. Mindfulness-based programs (MBPs) are evidence-based approaches that reduce psychological distress such as depression, anxiety, and stress while promoting well-being. MBPs may be particularly suited to the perinatal period, given concerns about psychotropic medication use during pregnancy...
Maternal mental health is a major global concern affecting both pregnant women and fetal development. Mindfulness-based interventions (MBIs) have shown benefits in improving maternal mental health. This study assessed the effects of digital and conventional face-to-face MBIs on psychological distress among pregnant women. Two independent reviewers conducted the literature search and study...
Esketamine nasal spray (NS) is an established treatment for patients with treatment resistant depression (TRD). To further optimise real-world outcomes, consensus is needed regarding strategies to enhance patient outcomes and decision-making factors for pivotal timepoints in esketamine NS treatment. This modified Delphi panel (3 rounds) established expert consensus (≥80% agreement) from 30...
JMIR Research ProtocolsJuly 17, 2026Santosha Veeramachaneni, Elizabeth Park, Jeffrey Martin et al.
Hypnosis is a focused state of consciousness that enhances concentration, attention, and responsiveness to suggestion. It has shown efficacy in treating psychiatric disorders such as depression, anxiety, and posttraumatic stress disorder (PTSD). However, its potential for addressing burnout and related symptoms remains underexplored. This systematic review and meta-analysis aims to assess the...
Zenodo (CERN European Organization for Nuclear Research)July 17, 2026Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka
preprint
Major depressive disorder is a highly burdensome psychiatric condition worldwide, and many patients do not achieve full remission after standard monoaminergic antidepressant treatment. This has contributed to growing interest in rapid-acting antidepressant interventionstargeting neurobiological pathways beyond traditional serotonin, norepinephrine, and dopamine mechanisms. This review...